Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Follow-Up Questions
Who is the CEO of Advicenne SA?
Mr. Didier Laurens is the Chief Executive Officer of Advicenne SA, joining the firm since 2021.
What is the price performance of ADVVF stock?
The current price of ADVVF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Advicenne SA?
Advicenne SA belongs to Pharmaceuticals industry and the sector is Health Care
What is Advicenne SA market cap?
Advicenne SA's current market cap is $NaN
Is Advicenne SA a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Advicenne SA, including 3 strong buy, 5 buy, 1 hold, 0 sell, and 3 strong sell
